Redeye updates its forecast and valuation following Modelon’s Q2 2025 report, which came broadly in line with expectations despite currency headwinds and softer solution services. While near-term visibility remains limited due to macro uncertainty, strong growth in Modelon Impact, continued improvements in operating efficiency, and a stable cash position—soon to be strengthened by a directed share issue—reinforce our conviction in the long-term investment case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/